Spots Global Cancer Trial Database for adoptive t cell therapy
Every month we try and update this database with for adoptive t cell therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | NCT02215967 | Myeloma, Plasma... Myeloma-Multipl... | Cyclophosphamid... Fludarabine Anti-B-cell mat... | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | NCT04561557 | Autoimmune Dise... Autoimmune Dise... Neuromyelitis O... Myasthenia Grav... Chronic Inflamm... Idiopathic Infl... Multiple Sclero... Autoimmune Ence... Myelin Oligoden... POEMS Syndrome | CT103A cells Cyclophosphamid... | 18 Years - 75 Years | Tongji Hospital | |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | NCT03958656 | Myeloma-Multipl... Myeloma, Plasma... | Cyclophosphamid... Fludarabine Rimiducid Anti-Signaling ... | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | NCT05798533 | Solid Tumor | Neo-T Toripalimab Tislelizumab | 18 Years - 75 Years | BGI, China | |
| HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors | NCT05895370 | Solid Tumor | HPV-T Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | NCT05797233 | Chronic Lymphoc... B-Cell Chronic ... Lymphoma, B-Cel... | Anti-CD19 and a... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | NCT05798546 | Solid Tumor | Neo-T Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | NCT05797233 | Chronic Lymphoc... B-Cell Chronic ... Lymphoma, B-Cel... | Anti-CD19 and a... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | NCT05798533 | Solid Tumor | Neo-T Toripalimab Tislelizumab | 18 Years - 75 Years | BGI, China | |
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | NCT02659943 | Lymphoma, B-Cel... Lymphoma, Non-h... | Anti-cluster of... Cyclophosphamid... Fludarabine | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | NCT05798546 | Solid Tumor | Neo-T Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | NCT01087294 | Leukemia, B-cel... Lymphoma, Hodgk... Lymphoma, Non-h... Lymphoma, B-Cel... | Allogeneic stem... Anti-CD19-chime... Leukapheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | NCT05798546 | Solid Tumor | Neo-T Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | NCT04555551 | Multiple Myelom... | Infusion of MCA... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | NCT02659943 | Lymphoma, B-Cel... Lymphoma, Non-h... | Anti-cluster of... Cyclophosphamid... Fludarabine | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | NCT04561557 | Autoimmune Dise... Autoimmune Dise... Neuromyelitis O... Myasthenia Grav... Chronic Inflamm... Idiopathic Infl... Multiple Sclero... Autoimmune Ence... Myelin Oligoden... POEMS Syndrome | CT103A cells Cyclophosphamid... | 18 Years - 75 Years | Tongji Hospital | |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | NCT02215967 | Myeloma, Plasma... Myeloma-Multipl... | Cyclophosphamid... Fludarabine Anti-B-cell mat... | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors | NCT05895370 | Solid Tumor | HPV-T Interleukin-2 | 18 Years - 75 Years | BGI, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
